Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H15NO5 |
| Molecular Weight | 241.2405 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC=C1OCC(O)COC(N)=O
InChI
InChIKey=GNXFOGHNGIVQEH-UHFFFAOYSA-N
InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)
| Molecular Formula | C11H15NO5 |
| Molecular Weight | 241.2405 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.drugbank.ca/drugs/DB00423Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/methocarbamol.html
Sources: http://www.drugbank.ca/drugs/DB00423
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/methocarbamol.html
Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect. Methocarbamol is used for use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. Under the trade name Robaxin, Methocarbamol is marketed by Actient Pharmaceuticals in the United States and Pfizer in Canada.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1460006 |
70.0 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Robaxin Approved UseRobaxin® and robaxin®-750 are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Launch Date1957 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
21.3 mg/L |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
28.7 mg/L |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
52.5 mg × h/L |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
87.1 mg × h/L |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.14 h |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.24 h |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
52% |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
51.9% |
1.5 g single, oral dose: 1.5 g route of administration: Oral experiment type: SINGLE co-administered: |
METHOCARBAMOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. | 2006-11-30 |
|
| Focal seizure following enflurane. | 1992-01 |
|
| Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. | 1990 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/methocarbamol.html
Usual Adult Dose for Muscle Spasm
Oral:
Initial dose: 1500 mg four times a day for the first 48 to 72 hours, up to a maximum dosage of 8 g/day for severe symptoms.
Maintenance dose: 4000 to 4500 mg/day in divided doses.
IV or IM:
1000 mg up to every 8 hours if necessary, not to exceed 3 g/day for more than 3 consecutive days except in the treatment of tetanus. A like course may be repeated after a lapse of 48 hours if the condition persists. Oral therapy should be instituted as soon as possible.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13453457
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:53 GMT 2025
by
admin
on
Mon Mar 31 17:36:53 GMT 2025
|
| Record UNII |
125OD7737X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
CFR |
21 CFR 522.1380
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
WHO-VATC |
QM03BA53
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
WHO-VATC |
QM03BA73
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
NDF-RT |
N0000175737
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
WHO-ATC |
M03BA03
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
WHO-VATC |
QM03BA03
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
LIVERTOX |
NBK548286
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
WHO-ATC |
M03BA53
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
CFR |
21 CFR 520.1380
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
WHO-ATC |
M03BA73
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
||
|
NDF-RT |
N0000175730
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
125OD7737X
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
m7322
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | Merck Index | ||
|
6829
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
532-03-6
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
DTXSID6023286
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
776
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
1747
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
4107
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
125OD7737X
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
1412008
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
SUB08852MIG
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
METHOCARBAMOL
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201117
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
208-524-3
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
DB00423
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
6845
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
D008721
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
C29252
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
100000081453
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
6832
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
170960
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY | |||
|
3122
Created by
admin on Mon Mar 31 17:36:53 GMT 2025 , Edited by admin on Mon Mar 31 17:36:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC |
|
||